OncoMatch/Clinical Trials/NCT07278479
Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors
Is NCT07278479 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies [212Pb]Pb-MP0712 for large cell neuroendocrine carcinoma.
Treatment: [212Pb]Pb-MP0712 — The purpose of this study is to evaluate the safety, tolerability, dosimetry and preliminary efficacy of \[212Pb\]Pb-MP0712, in patients aged ≥18 years with Small Cell Lung Cancer and other locally advanced or metastatic DLL3 positive tumors.
Check if I qualifyExtracted eligibility criteria
Cancer type
Neuroendocrine Tumor
Small Cell Lung Cancer
Biomarker criteria
Required: DLL3 expression by IHC
other epNECs with previously confirmed DLL3 expression by IHC
Required: DLL3 positivity by [203Pb]Pb-DOTAM-MAM279 SPECT/CT
DLL3-positivity by [203Pb]Pb-DOTAM-MAM279 SPECT/CT
Disease stage
Required: Stage IV, III
advanced extensive or limited SCLC or LC NECs of the lung; at least one measurable disease per RECIST v1.1
Prior therapy
Must have received: platinum-based chemotherapy — systemic
SCLC (extensive stage, or limited stage) patients with progression or recurrence following at least two prior line of systemic platinum based therapy and immunotherapy
Must have received: immunotherapy — systemic
SCLC (extensive stage, or limited stage) patients with progression or recurrence following at least two prior line of systemic platinum based therapy and immunotherapy
Must have received: systemic therapy — systemic
LC NEC of the lung patients with progression or recurrence following at least one prior line of systemic therapy
Must have received: systemic therapy — systemic
epNECs with progression or recurrence following at least one prior line of systemic therapy
Lab requirements
Blood counts
hemoglobin ≥9 g/dl; absolute neutrophil count (anc) ≥1.5 × 10^9/l; platelets ≥100 × 10^9/l; white blood cells (wbc) ≥2.5 x 10^9/l
Kidney function
calculated glomerular filtration rate (gfr) >60ml/min (using cockroft-gault formula)
Liver function
adequate hepatic function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Nebraska Cancer Specialists · Omaha, Nebraska
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify